Table of Contents List of Tables List of Figures Introduction Global Markets Direct Report Coverage Restless Legs Syndrome - Overview Restless Legs Syndrome - Therapeutics Development Pipeline Overview Pipeline by Companies Products under Development by Companies Restless Legs Syndrome - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Restless Legs Syndrome - Companies Involved in Therapeutics Development Axim Biotechnologies Inc Bioprojet SCR Hisamitsu Pharmaceutical Co Inc Merz Pharma GmbH & Co KgaA Omeros Corp Relmada Therapeutics Inc Serina Therapeutics Inc Vifor Pharma Ltd Restless Legs Syndrome - Drug Profiles (cannabidiol + dronabinol) - Drug Profile Product Description Mechanism Of Action R&D Progress (cannabidiol + gabapentin) - Drug Profile Product Description Mechanism Of Action R&D Progress aplindore fumarate - Drug Profile Product Description Mechanism Of Action R&D Progress BP-1.4979 - Drug Profile Product Description Mechanism Of Action R&D Progress ferric carboxymaltose - Drug Profile Product Description Mechanism Of Action R&D Progress incobotulinumtoxin A - Drug Profile Product Description Mechanism Of Action R&D Progress NLS-2 - Drug Profile Product Description Mechanism Of Action R&D Progress OMS-527 - Drug Profile Product Description Mechanism Of Action R&D Progress REL-1017 - Drug Profile Product Description Mechanism Of Action R&D Progress ropinirole hydrochloride - Drug Profile Product Description Mechanism Of Action R&D Progress SER-214 - Drug Profile Product Description Mechanism Of Action R&D Progress Restless Legs Syndrome - Dormant Projects Restless Legs Syndrome - Discontinued Products Restless Legs Syndrome - Product Development Milestones Featured News & Press Releases Oct 23, 2014: Hisamitsu Announces the results of Phase II clinical study of HP-3000 in Japan (a transdermal system for the treatment of idiopathic restless legs syndrome) Oct 16, 2008: Neurogen Announces Positive Top-Line Results From Two Phase II Trials For Aplindore In Restless Legs Syndrome And Parkinson's Disease Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer

List of Tables Number of Products under Development for Restless Legs Syndrome, H1 2019 Number of Products under Development by Companies, H1 2019 Products under Development by Companies, H1 2019 Number of Products by Stage and Target, H1 2019 Number of Products by Stage and Mechanism of Action, H1 2019 Number of Products by Stage and Route of Administration, H1 2019 Number of Products by Stage and Molecule Type, H1 2019 Restless Legs Syndrome - Pipeline by Axim Biotechnologies Inc, H1 2019 Restless Legs Syndrome - Pipeline by Bioprojet SCR, H1 2019 Restless Legs Syndrome - Pipeline by Hisamitsu Pharmaceutical Co Inc, H1 2019 Restless Legs Syndrome - Pipeline by Merz Pharma GmbH & Co KgaA, H1 2019 Restless Legs Syndrome - Pipeline by Omeros Corp, H1 2019 Restless Legs Syndrome - Pipeline by Relmada Therapeutics Inc, H1 2019 Restless Legs Syndrome - Pipeline by Serina Therapeutics Inc, H1 2019 Restless Legs Syndrome - Pipeline by Vifor Pharma Ltd, H1 2019 Restless Legs Syndrome - Dormant Projects, H1 2019 Restless Legs Syndrome - Discontinued Products, H1 2019List of Figures Number of Products under Development for Restless Legs Syndrome, H1 2019 Number of Products under Development by Companies, H1 2019 Number of Products by Top 10 Targets, H1 2019 Number of Products by Stage and Top 10 Targets, H1 2019 Number of Products by Top 10 Mechanism of Actions, H1 2019 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019 Number of Products by Routes of Administration, H1 2019 Number of Products by Stage and Routes of Administration, H1 2019 Number of Products by Molecule Types, H1 2019 Number of Products by Stage and Molecule Types, H1 2019

Axim Biotechnologies Inc Bioprojet SCR Hisamitsu Pharmaceutical Co Inc Merz Pharma GmbH & Co KgaA Omeros Corp Relmada Therapeutics Inc Serina Therapeutics Inc Vifor Pharma Ltd